Abstract
The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer. 38 patients with advanced or metastatic colorectal carcinoma with documented progression on or within 6 months following 5-FU or thymidylate synthase inhibitor containing chemotherapy were recruited between June 1997 and September 2000. Oxaliplatin (100 mg m–2) was given every 2 weeks and PVI 5-FU (300 mg m–2day–1) was administered. Median age of patients was 61 years. 17 patients had >2 sites of disease involvement. 10 had received 5-FU based adjuvant chemotherapy. 16 received oxaliplatin and PVI 5-FU as second-line chemotherapy for advanced disease and 22 as third or subsequent lines. Median follow up was 6.1 months. The best achieved objective tumour response rate was 29% (11 partial responses 95% confidence interval [CI] = 15–46%). 20 patients (52.6%) had stable disease. The median duration of response was 3.9 months. Even for patients who had previously received both 5-FU and irinotecan (n= 22), 27.3% had partial response with oxaliplatin and PVI 5-FU. 37 patients had symptoms on entry into the study. 25 patients had pain, 10 had anorexia and 28 had lethargy. 64%, 70% and 17.9% had symptomatic improvement after treatment respectively. Grade 3–4 toxicities were anaemia 10.6%, neutropenia 2.6%, thrombocytopenia 5.2%, diarrhoea 18.9%, nausea and vomiting 2.7%, infection 5.4% and lethargy 37.8%. The median survival was 9.1 months. Probability of overall survival at 6 months was 58.4% (95% CI = 38.7–73.7%). The median failure-free survival was 4 months. Oxaliplatin and PVI 5FU is an active and well tolerated regimen in patients with heavily pre-treated advanced colorectal cancer. © 2001 Cancer Research Campaign www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adenis A, Douillard JY, Lacroix H, Dufour P, Tubiana N, Berger C, Bugat R, Mousseau M, Block S and Dupont-Andre G (2000) Randomized phase II-III trial of oxaliplatin (OXA) with 5-fluorouracil continuous infusion versus a control arm with either 5FU or irinotecan in previously treated metastatic colorectal cancer patients. Proc Am Soc Clin Oncol 19: 279a
Allen M, Cunningham D and Schmitt C (1998) The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies. Anticancer Drugs 9: 783–790
Andre T, Louvet C, Raymond E, Tournigand C and de Gramont A (1998) Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 9: 1251–1253
Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Morvan F, Dupont-Andre G and de Gramont A (1999) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17: 3560–3568
Armand JP, Boige V, Raymond E, Fizazi K, Faivre S and Ducreux M (2000) Oxaliplatin in colorectal cancer: an overview. Semin Oncol 27: 96–104
Brienza S, Bensmaine MA, Soulie P, Louvet C, Gamelin E, Francois E, Ducreux M, Marty M, Andre T, de Braud F, Bleiberg H, Segal V, Itzhaki M and Cvitkovic E (1999) Oxaliplatin added to 5-fluorouracil-based therapy (5-FU+/– FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. Ann Oncol 10: 1311–1316
Cunningham D and James RD (2001) Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. European Journal of Cancer 37: 826–834
Cunningham D, Pyrhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen T, Starkhammar H, Topham CA, Awad L, Jacques C and Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413–1418
de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, Raymond E, Moreau S, Le Bail N and Krulik M (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214–219
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938–2947
Douillard JY, Michel P, Gamelin E, Conroy T, Francois E, Raoul JL, Becouarn Y, Cvitkovic B, Nasca S, Ychou M, Fandi A and Seitz JF (2000) Raltitrexed (‘Tomudex’) plus oxaliplatin: an active combination for first line chemotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 19: 250a
Fizazi K, Ducreux M, Ruffie P, Bonnay M, Daniel C, Soria JC, Hill C, Fandi A, Poterre M, Smith M and Armand JP (2000) Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol 18: 2293–2300
Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL and Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136–147
Glimelius B, Hoffman K, Graf W, Pahlman L and Sjoden PO (1994) Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 73: 556–562
Goldwasser F, Gross-Goupil M, Tigaud JM, Di Palma M, Marceau-Suissa J, Wasserman E, Yovine A, Misset JL and Cvitkovic E (2000) Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Annals of Oncology 11: 1463–1470
Gornet JM, Azoulay D, Levi F, Yovine A, Misset JL and Goldwasser F (2000) Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient. Anticancer Drugs 11: 263–268
Graham MA, Lockwood GF, Cunningham D and Gamelin E (1999) Pharmacokinetics of oxaliplatin in special patient populations. Proc Am Soc Clin Oncol 18: 189
Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M and Gamelin E (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6: 1205–1218
Hejna M, Kostler WJ, Raderer M, Tomek S, Brodowicz T, Scheithauer W, Wiltschke C and Zielinski CC (2000) Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. Anti-Cancer Drugs 11: 629–634
Levi F, Zidani R and Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350: 681–686
Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A and Focan C (1999) A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 85: 2532–2540
Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M and Dogliotti L et al (1994) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86: 1608–1617
Lokich J, Fine N, Perri J and Bothe A Jr. (1983) Protracted ambulatory venous infusion of 5-fluorouracil. Am J Clin Oncol 6: 103–107
Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425–432
Macdonald JS, Haller D and Mayer RJ (1995) Grading of Toxicity. InManual of Oncologic Therapeutics, 519–523, Lippincott: Philadelphia
Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, D ND, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF and Ychou M (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95–98
Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M and de Gramont A (1999) Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35: 1338–1342
Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Mabro M, Artru P, Gilles V, Lotz JP, Izrael V and Krulik M (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37: 1000–1005
Martoni A, Mini E, Pinto C, Nobili S, Gentile AL, Dentico P, Angelelli B, Scicolone S, Piana E and Mazzei T (2001) Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Annals of Oncology 12: 519–524
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Misset JL and Allain, (1995) Pharmacokinetics, urinary, and fecal excretion of oxaliplatin in cancer patients. TDR 3500. Debiopharm/Sanofi,
Office for National Statistics Cancer Survival Trends in England & Wales 1971–1995. (1999). Office for National Statistics
Papamichael D, Joel S, Seymour M, Richards F, Bowerbank M, Slevin ML and Graham M (1998) Pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. INT3681. Sanofi Research,
Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P and Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407–1412
Scheithauer W, Kornek GV, Ulrich-Pur H, Penz M, Raderer M, Salek T, Haider K, Kwasny W and Depisch D (2001) Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma – Results of a phase I-II trial. Cancer 91: 1264–1271
The Advanced Colorectal Cancer Meta-Analysis Project (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 16: 301–308
Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Herait P and Bleiberg H (1999) Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 35: 54–59
Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Mery-Mignard D, Ouldkaci M, Besmaine A, Dupont-Andre G, Mahjoubi M, Marty M, Misset JL and Cvitkovic E (1999) Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 17: 1751–1759
Zeuli M, Di Costanzo F, Sdrobolini A, Paoloni FP, Carpi A, Moscetti L, Cherubini R and Cognetti F (2000) A dose-finding study of capecitabine in combination with oxaliplatin (L-OHP) in advanced colorectal cancer (CRC). Annals of Oncology 11: H61
Author information
Authors and Affiliations
Additional information
Presented at the 37th Annual Meeting of the American Society of Clinical Oncology, May 2001.
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Chau, I., Webb, A., Cunningham, D. et al. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 85, 1258–1264 (2001). https://doi.org/10.1054/bjoc.2001.2036
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2036
Keywords
This article is cited by
-
Third-line therapy for metastatic colorectal cancer
Cancer Chemotherapy and Pharmacology (2007)
-
Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer
Current Colorectal Cancer Reports (2006)